Filtered By:
Management: Government
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 334 results found since Jan 2013.
Allergy and Immunology Physician Workforce
Nearly 15 years ago, an American College of Allergy, Asthma, and Immunology (ACAAI) White Paper estimated that the number of full-time equivalent allergist/immunologists would decline 7% from 3660 in 2006 to 3400 in 2020, whereas demand was projected to increase by 35% to more than 5500. It concluded that the federal government was the only entity that had the resources to fund training of the next generation of physicians.1 Hampering efforts to expand graduate medical education (GME) is a continuing rule from the 1990s that caps the total number of GME slots.
Source: Annals of Allergy, Asthma and Immunology - June 17, 2021 Category: Allergy & Immunology Authors: Alnoor Malick, J. Allen Meadows Tags: Perspective Source Type: research
The Delta Variant Could Soon Become the Dominant COVID-19 Strain. Here ’s What You Need to Know
The COVID-19 pandemic is increasingly becoming an arms race among the emerging variants of the virus, and at the moment, there’s no question which one is winning: the Delta variant—formally known as B.1.617.2—one of four strains to have emerged originally in India. It was just last month that the World Health Organization labeled Delta a “variant of concern”—joining with the Alpha strain, which emerged in the U.K.; the Beta strain, from South Africa; and the Gamma strain, first seen in Brazil. But Delta is fast becoming the most worrisome of the bunch.
Health officials are sounding the a...
Source: TIME: Science - June 15, 2021 Category: Science Authors: Alejandro de la Garza and Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
Skin Prick Test Practice In Allergy Clinics During Covid-19 Pandemic
Skin prick test (SPT) is a vital tool to confirm sensitization in allergic diseases, making it a daily routine for allergists. Although SPT is not considered an aerosol-generating procedure, the close contact between the patient and the performer may pose a risk for transmitting the disease.1 For Turkish healthcare facilities, the first phase of the COVID-19 pandemic started with identifying the first case and continued by a quarantine period (QP), declared at the end of March 2020. At the beginning of June 2020, the Turkish government initiated the second period and named it the “normalization period” (NP).
Source: Annals of Allergy, Asthma and Immunology - May 18, 2021 Category: Allergy & Immunology Authors: Resat Kendirlinan, Pamir Cerci, Dilsad Mungan Tags: Letters Source Type: research
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
The Pandemic Remade Every Corner of Society. Now It ’s the Climate’s Turn
On her third day as the Secretary of Housing and Urban Development, Marcia Fudge phoned the White House. She had taken over an agency with a role to play addressing a range of crises as the lack of affordable housing in U.S. cities has left hundreds of thousands homeless and millions more in financial straits. She connected with Joe Biden’s climate team. Fudge and Gina McCarthy, Biden’s national climate adviser, talked about addressing climate change and the affordable-housing shortage at the same time. Three weeks later, the Administration announced plans to provide for more than 1 million resilient and e...
Source: TIME: Science - April 15, 2021 Category: Science Authors: Justin Worland Tags: Uncategorized climate change Cover Story feature Magazine TIME 2030 Source Type: news
PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an *
In the Dragonfly:
*NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open
The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news
Vaccine Safety Board Chides AstraZeneca for Using ‘Outdated’ Data in Press Release About its COVID-19 Shot
In an unusual move, on March 23 the U.S. National Institute of Allergy and Infectious Diseases (NIAID) issued a strongly worded statement asking AstraZeneca to “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”
On March 22, AstraZeneca released the results of its long-awaited U.S. trial of its COVID-19 vaccine, developed with scientists from Oxford University’s Jenner Institute. The data showed that the two-dose vaccine was 79% efficacious in protecting people from symptoms of COVID-19, and 100% efficacious in protecting against severe disease.
That data, however, ...
Source: TIME: Health - March 23, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson ’s COVID-19 Vaccine Results Are Better Than They May Sound
Johnson & Johnson’s Janssen Pharmaceutical Companies announced on Jan. 29 that its one-shot COVID-19 vaccine is 66% effective in protecting against disease, but 85% effective against preventing severe disease—results that could make it especially valuable in the effort to vaccinate parts of the world with weak health care systems.
By comparison, the vaccines already authorized in the U.S.—one from Moderna and one from Pfizer-BioNTech—each require two doses, spaced three to four weeks apart. Janssen’s vaccine can also be stored in normal refrigerators, unlike Moderna’s and Pfizer-BioN...
Source: TIME: Health - January 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Biden ’s First Three Steps to Getting COVID-19 Vaccines to Every American
Less than a week after taking office, President Joe Biden announced three major steps to improve the country’s vaccination plans, and his Administration’s COVID-19 response team held its first press briefing.
On Jan. 26, the President outlined the first three steps his team will take as part of a National Action Strategy for responding to the pandemic. First, the Administration will increase minimum weekly shipments of vaccines to states to 10 million doses, from the current 8.6 million. Next, Biden guaranteed these shipment numbers for the next three weeks, which allows states to plan out for the next month ho...
Source: TIME: Health - January 27, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Fauci on What Working for Trump Was Really Like
From denialism to death threats, Dr. Anthony S. Fauci describes a fraught year as an adviser to President Donald J. Trump on the Covid-19 pandemic.
Source: NYT - January 25, 2021 Category: American Health Authors: Donald G. McNeil Jr. Tags: Fauci, Anthony S Trump, Donald J Coronavirus (2019-nCoV) National Institute of Allergy and Infectious Diseases Threats and Threatening Messages Rumors and Misinformation United States Politics and Government your-feed-health your-feed-scie Source Type: news
